Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology 2018, 4: 210-216. PMID: 29270615, PMCID: PMC5838598, DOI: 10.1001/jamaoncol.2017.4427.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaAdvanced non-small cell lung carcinomaSecond-line therapyCheckpoint inhibitorsOverall survivalCell lung carcinomaWild-type subgroupClinicopathological characteristicsHazard ratioClinical trialsLung carcinomaMutant subgroupSystematic reviewKRAS wild-type subgroupStandard second-line therapyKRAS mutant subgroupRelative treatment benefitOverall survival benefitCochrane Central RegisterType of chemotherapyProlonged overall survivalProlongs overall survivalEGFR-mutant tumorsPatients' clinicopathological characteristicsRandomized clinical trials